Perspective Therapeutics
CATX
132 hedge funds and large institutions have $298M invested in Perspective Therapeutics in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 61 increasing their positions, 26 reducing their positions, and 29 closing their positions.
45,100% more call options, than puts
Call options by funds: $452K | Put options by funds: $1K
135% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 26
6.35% more ownership
Funds ownership: 70.14% → 76.49% (+6.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 138 → 132 (-6)
11% less capital invested
Capital invested by funds: $333M → $298M (-$35.5M)
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.79M |
| 4 |
SSC
Spruce Street Capital
New York
|
+$4.03M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$3.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$19.5M |
| 2 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$6.78M |
| 3 |
VC
Vestor Capital
Chicago,
Illinois
|
-$4.15M |
| 4 |
Morgan Stanley
New York
|
-$4.05M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$3.3M |
CATX Hedge Fund Activity: Q2 2026 in Review
132 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2026, worth a combined $298M — down 11% from $333M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CATX and 24 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 61 added.
The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Opaleye Management, exiting entirely with an estimated $19.5M sold.
- 132 institutional investors held Perspective Therapeutics (CATX) as of Q2 2026, down from 138 in Q1 2026.
- Funds reported $298M of Perspective Therapeutics stock for Q2 2026, down 11% quarter-over-quarter.
- 24 funds opened new Perspective Therapeutics positions in Q2 2026 and 29 closed out, a net change of -5 holders.
- The largest Perspective Therapeutics buyer in Q2 2026 was BlackRock, an estimated $15.7M added.
- The largest Perspective Therapeutics seller in Q2 2026 was Opaleye Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q2 2026.